BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809
1466 results:

  • 1. Endometriosis-Associated Ovarian cancer: From Molecular Pathologies to Clinical Relevance.
    Steinbuch SC; Lüß AM; Eltrop S; Götte M; Kiesel L
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673891
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Therapeutic potential of targeting Nrf2 by panobinostat in pituitary neuroendocrine tumors.
    Cheng Y; Dai Y; Tang H; Lu X; Xie J; Xie W; Zhang Q; Liu Y; Lin S; Yao H; Shang H; Yang K; Liu H; Wu X; Zhang J; Zhang X; Xue L; Wu ZB
    Acta Neuropathol Commun; 2024 Apr; 12(1):61. PubMed ID: 38637883
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. IFNα-induced BST2
    Zheng C; Wang J; Zhou Y; Duan Y; Zheng R; Xie Y; Wei X; Wu J; Shen H; Ye M; Kong B; Liu Y; Xu P; Zhang Q; Liang T
    Cell Rep; 2024 Apr; 43(4):114088. PubMed ID: 38602878
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line.
    Çoban HŞ; Çil N; Önder E; Abban Mete G
    Mol Biol Rep; 2024 Apr; 51(1):485. PubMed ID: 38578399
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Novel acrylonitrile derived imidazo[4,5-b]pyridines as antioxidants and potent antiproliferative agents for pancreatic adenocarcinoma.
    Boček Pavlinac I; Persoons L; Daelemans D; Starčević K; Vianello R; Hranjec M
    Int J Biol Macromol; 2024 May; 266(Pt 2):131239. PubMed ID: 38569992
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Diosgenin inhibits proliferation and migration of ovarian cancer cells and induce apoptosis via upregulation of PTEN.
    Fang F; Zhang X; Fang Y
    Chem Biol Drug Des; 2024 Mar; 103(3):e14459. PubMed ID: 38538058
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
    Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
    World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mtor signaling axis by binding to MYH9.
    Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
    Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer.
    Zhu SL; Qi M; Chen MT; Lin JP; Huang HF; Deng LJ; Zhou XW
    Phytomedicine; 2024 Jun; 128():155377. PubMed ID: 38503154
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. The roles of autophagy, ferroptosis and pyroptosis in the anti-ovarian cancer mechanism of harmine and their crosstalk.
    Zhu J; Zhu H; Zhu Q; Xu SL; Xiao L; Zhang MY; Gao J
    Sci Rep; 2024 Mar; 14(1):6504. PubMed ID: 38499622
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures.
    Rausio H; Cervera A; Heuser VD; West G; Oikkonen J; Pianfetti E; Lovino M; Ficarra E; Taimen P; Hynninen J; Lehtonen R; Hautaniemi S; Carpén O; Huhtinen K
    Neoplasia; 2024 May; 51():100987. PubMed ID: 38489912
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells.
    Mikhael S; Kurdi A; Khoueiry-Zgheib N; Tahtouh R; Nasr R; Hilal G
    PLoS One; 2024; 19(3):e0298127. PubMed ID: 38489280
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Activity of the Ubiquitin-activating Enzyme Inhibitor TAK-243 in Adrenocortical Carcinoma Cell Lines, Patient-derived Organoids, and Murine Xenografts.
    Arakawa Y; Jo U; Kumar S; Sun NY; Elloumi F; Thomas A; Roper N; Varghese DG; Takebe N; Zhang X; Ceribelli M; Holland DO; Beck E; Itkin Z; McKnight C; Wilson KM; Travers J; Klumpp-Thomas C; Thomas CJ; Hoang CD; Hernandez JM; Del Rivero J; Pommier Y
    Cancer Res Commun; 2024 Mar; 4(3):834-848. PubMed ID: 38451783
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Defects of mitochondria-lysosomes communication induce secretion of mitochondria-derived vesicles and drive chemoresistance in ovarian cancer cells.
    Gagliardi S; Mitruccio M; Di Corato R; Romano R; Aloisi A; Rinaldi R; Alifano P; Guerra F; Bucci C
    Cell Commun Signal; 2024 Mar; 22(1):165. PubMed ID: 38448982
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. TOP2A modulates signaling via the AKT/mtor pathway to promote ovarian cancer cell proliferation.
    Zhang K; Zheng X; Sun Y; Feng X; Wu X; Liu W; Gao C; Yan Y; Tian W; Wang Y
    Cancer Biol Ther; 2024 Dec; 25(1):2325126. PubMed ID: 38445610
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
    Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
    J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
    Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
    J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The miR-1290/OGN axis in ovarian cancer-associated fibroblasts modulates cancer cell proliferation and invasion.
    Jiang B; Xiao S; Zhang S; Xiao F
    J Ovarian Res; 2024 Feb; 17(1):52. PubMed ID: 38402185
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Complexity of the Genetic Background of Oncogenesis in Ovarian cancer-Genetic Instability and Clinical Implications.
    Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Deep response to a combination of mtor inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
    Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
    Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 74.